期刊文献+

老年心房颤动病人华法林抗凝治疗的有效性安全性评价 被引量:3

Assessment of effectiveness and security of wanfarin in treatment of anticoagulation in old patients with Chronic Atrial Fibrillation
下载PDF
导出
摘要 目的 评价华法林用于老年心房颤动病人抗凝治疗的有效性、安全性。方法 选择符合本研究抗凝标准的132例老年心房颤动病人随机分为两组 ,华法林治疗组 (治疗组 ) 5 8例 ,给予华法林 3mg/ d开始 ,监测凝血酶原时间(PT)及国际标准化比值 (INR) ,7~ 15 d使 INR达到 1.8~ 2 .5范围内 ,以后每月查 1次 INR。若病人增加或减少药物有出血倾向时随时再测 INR。阿司匹林对照组 (对照组 ) 74例 ,给予阿司匹林 30 0 mg/ d,分 2次口服 ,密切随访。结果 治疗组 7~ 15 d,平均 (9.1± 2 .8) d,INR达 1.8~ 3.0 (平均 2 .1± 0 .13) ,其中 INR在 1.8~ 2 .5 (平均 1.92±0 .2 3)之间者占 92 .7% ,治疗组有 1例心瓣膜病人出现脑梗死 ,而对照组有 7例发生脑梗死 ,差异显著 ,其余不良反应率两组差异无显著性。结论 老年心房颤动病人选择华法林 2~ 3mg/ d时 ,加强服药后监测及各药物间的相互作用 ,使 INR保持在 1.8~ 2 .5之间是有效。 Objective To assess the effectiveness and security of wanfarin in treatment of anticoagulation in old patients with chronic atrial fibrillation. Method The patients of chronic atrial fibrillation who were coincidence with ainticoagulation condition were divided into two groups at random, oral wanfarin treatment group and control group. PT and INR of the whole patients were detected, the treatment group were administed 3mg/d dose of warfarin. INR is in the range of 1.8-2.5 after 7-15 days, and from then on, INR were detected every month. When the patients were inclined to hemorrhagia symptom, their INR was detected immediately. The patients of control group were administered aspirin 300mg orally twice a day. Results INR of the treatment group attained to 1.8- 3.0 after 7-15(9.1±2.8) days. It takes 92.7% of the patients in the treatment group whose INR were attained to 1.8-2.5(1.92±0.23). Only one case of the treatment group was found cerebral embolism, while 6 in the control group, there was significant difference. However, there was no any other significant difference in complications. Conclusion 2-3mg dose of oral warfarin in old chronic Af patients with INR in the range of 1.8-2.5 is effetive,safe and convenient.
出处 《中国心血管杂志》 2003年第6期426-428,共3页 Chinese Journal of Cardiovascular Medicine
关键词 老年心房颤动 华法林 有效性 安全性 Old patients with chronic atrial fibrillation Wanfarin Effetiveness security
  • 相关文献

参考文献7

  • 1马长生,周玉杰,马煜,郑知刚,颜红兵,王勇,李霄,柯元南,汤旦林.北京地区非瓣膜病心房颤动患者缺血性脑卒中发生率及影响因素的随访研究[J].中华心血管病杂志,2002,30(3):165-167. 被引量:148
  • 2Ezekowize MD, Levine JA. Prevention stoke in patient with atrial fibrillation[J]. JAMA, 1999, 281:1830-1835.
  • 3Furberg CD. Prevalance of artrial fibrillatoon in elderly subjects[J]. Am J Cardiol, 1994, 74:236-241.
  • 4Afrial fibrillation investigators. Risk factios for stroke and efficacy of antithrombotic therapy in atrial fibrillation :analysis of pooled data from five randomized controlled trials[J]. Arch Intern Med, 1994, 154:1449-1457.
  • 5Mugge A. Anticoagulation in patient with AF[J].Herz, 1996,21 : 28-36.
  • 6Morley J,marineluk R, Rials ST, et al. Af,anticongulation and stroke[J], Am J Cardiol, 1996, 77:38-44.
  • 7Hylck EM,Skates SJ, Sheeham MA, et al. An analysis of the lowest effective intensify of prophy lactic anticongulation for patients with non-rheumatic atrial fibrillation[J]. N Eng J Med, 1996,335:540-546.

二级参考文献10

  • 1Saoudi N,Schoels W,EL-Sherif N,eds.Atrial flutter and fibrillation:from basic to clinical applications[]..1998
  • 2Wolf PA,Abbott RD,Kannel WB.Atrial fibrillation as an independent risk factor for stroke: the Framingham study[].Stroke.1991
  • 3Caro JJ,Flegel KM,Orejuela ME,et al.Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice[].Canadian Medical Association Journal.1999
  • 4Flegel KM,Shipley MJ,Rise G.Risk of stroke in non-rheumatic atrial fibrillation[].The Lancet.1987
  • 5Yamaguchi T.Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation[].Stroke.2000
  • 6Hart RG,Sherman DG,Easton JD,et al.Prevention of stroke in patients with nonvalvular atrial fibrillation[].Neurology.1998
  • 7Peterson P,Boysen G,Godtfredsen J,et al.Placebo controlled,randomized trial of warfarin and aspirin for prevention of thromboembolic complications on chronic atrial fibrillation: the Compenhagen AFASAK study[].The Lancet.1989
  • 8Feinberg WM,Blackshear JL,Laupacis A,et al.Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications[].Archives of Internal Medicine.1995
  • 9Ezekowitz MD,Bridgers SL,James KE,et al.Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation:Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators[].The New England Journal of Medicine.1992
  • 10Connolly SJ,Laupacis A,Gent M,et al.Canadian atrial fibrillation anticoagulation (CAFA) study[].Journal of the American College of Cardiology.1991

共引文献147

同被引文献9

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部